Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$2.02 USD
-0.06 (-2.89%)
Updated Nov 15, 2024 11:48 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
FATE 2.02 -0.06(-2.89%)
Will FATE be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FATE
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Other News for FATE
Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges
Hold Rating for Fate Therapeutics Amid Promising Trials and Financial Prudence
Optimistic Outlook for Fate Therapeutics Amid Promising Cell Therapy Developments
Cautious Hold Rating for Fate Therapeutics Amidst Clinical Uncertainties and Financial Stability
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)